EcoR1 Capital as of Dec. 31, 2019
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 43 positions in its portfolio as reported in the December 2019 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Prothena (PRTA) | 13.7 | $149M | 9.4M | 15.83 | |
Fibrogen (FGEN) | 8.5 | $93M | 2.2M | 42.89 | |
Dicerna Pharmaceuticals | 7.3 | $80M | 3.6M | 22.03 | |
Xencor (XNCR) | 6.2 | $68M | 2.0M | 34.39 | |
Kura Oncology (KURA) | 5.3 | $58M | 4.2M | 13.75 | |
Ironwood Pharmaceuticals (IRWD) | 5.3 | $58M | 4.4M | 13.31 | |
Arvinas Ord (ARVN) | 5.0 | $55M | 1.3M | 41.09 | |
Assembly Biosciences | 4.5 | $49M | 2.4M | 20.46 | |
Neoleukin Therapeutics | 4.4 | $48M | 3.9M | 12.32 | |
Morphic Hldg (MORF) | 3.4 | $37M | 2.2M | 17.16 | |
Prevail Therapeutics Ord | 3.3 | $36M | 2.2M | 15.83 | |
Argenx Se (ARGX) | 3.0 | $32M | 202k | 160.52 | |
Anaptysbio Inc Common (ANAB) | 2.9 | $32M | 2.0M | 16.25 | |
Innate Pharma (IPHA) | 2.7 | $29M | 4.5M | 6.44 | |
BioMarin Pharmaceutical (BMRN) | 2.4 | $26M | 313k | 84.55 | |
Merus N V (MRUS) | 2.2 | $24M | 1.7M | 14.08 | |
Atreca Inc Cl A (BCEL) | 2.1 | $23M | 1.5M | 15.47 | |
ACADIA Pharmaceuticals (ACAD) | 2.0 | $21M | 500k | 42.78 | |
Chiasma | 1.4 | $15M | 3.0M | 4.96 | |
Harpoon Therapeutics | 1.2 | $13M | 909k | 14.79 | |
Sage Therapeutics (SAGE) | 1.1 | $13M | 173k | 72.19 | |
Ultragenyx Pharmaceutical (RARE) | 1.0 | $11M | 262k | 42.71 | |
Selecta Biosciences | 1.0 | $11M | 4.6M | 2.38 | |
Exicure | 0.9 | $10M | 3.5M | 2.86 | |
Pieris Pharmaceuticals | 0.8 | $9.2M | 2.5M | 3.62 | |
Fate Therapeutics (FATE) | 0.8 | $8.8M | 451k | 19.57 | |
Mirati Therapeutics | 0.8 | $8.4M | 65k | 128.86 | |
Arcus Biosciences Incorporated (RCUS) | 0.7 | $7.4M | 730k | 10.10 | |
Evolus (EOLS) | 0.7 | $7.3M | 600k | 12.17 | |
Eiger Biopharmaceuticals | 0.6 | $6.7M | 449k | 14.90 | |
Savara (SVRA) | 0.6 | $6.4M | 1.4M | 4.48 | |
Iovance Biotherapeutics (IOVA) | 0.5 | $5.9M | 214k | 27.68 | |
Rubius Therapeutics | 0.5 | $5.0M | 526k | 9.50 | |
Cyclerion Therapeutics | 0.5 | $4.9M | 1.8M | 2.72 | |
X4 Pharmaceuticals (XFOR) | 0.4 | $4.4M | 415k | 10.70 | |
Corvus Pharmaceuticals (CRVS) | 0.4 | $4.0M | 738k | 5.44 | |
Aclaris Therapeutics (ACRS) | 0.4 | $3.9M | 2.1M | 1.89 | |
Igm Biosciences (IGMS) | 0.3 | $3.8M | 100k | 38.16 | |
Cytomx Therapeutics (CTMX) | 0.3 | $3.4M | 410k | 8.31 | |
Tcr2 Therapeutics Inc cs | 0.3 | $3.4M | 240k | 14.28 | |
Surface Oncology | 0.2 | $2.4M | 1.3M | 1.88 | |
Vericel (VCEL) | 0.2 | $2.3M | 131k | 17.40 | |
Urovant Sciences | 0.0 | $411k | 27k | 15.53 |